{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:27:10Z","timestamp":1761989230376,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T00:00:00Z","timestamp":1530662400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00228-018-2509-2","type":"journal-article","created":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T10:32:20Z","timestamp":1530700340000},"page":"1121-1130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril\/valsartan (LCZ696) in healthy subjects"],"prefix":"10.1007","volume":"74","author":[{"given":"Uwe","family":"Schuehly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surya","family":"Ayalasomayajula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeppe","family":"Buchbjerg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parasar","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Golor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret F.","family":"Prescott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gangadhar","family":"Sunkara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Hinder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas H.","family":"Langenickel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,4]]},"reference":[{"issue":"11","key":"2509_CR1","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","volume":"133","author":"SA Hubers","year":"2016","unstructured":"Hubers SA, Brown NJ (2016) Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation 133(11):1115\u20131124. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018622","journal-title":"Circulation"},{"key":"2509_CR2","unstructured":"Novartis (2015) Entresto (sacubitril\/valsartan): US prescribing information"},{"issue":"4","key":"2509_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0091270009343932","volume":"50","author":"J Gu","year":"2010","unstructured":"Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Lin TH, Zheng W, Dole WP (2010) Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 50(4):401\u2013414. \n                    https:\/\/doi.org\/10.1177\/0091270009343932","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"2509_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1161\/01.HYP.0000258532.07418.fa","volume":"49","author":"DG Gardner","year":"2007","unstructured":"Gardner DG, Chen S, Glenn DJ, Grigsby CL (2007) Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. Hypertension 49(3):419\u2013426. \n                    https:\/\/doi.org\/10.1161\/01.HYP.0000258532.07418.fa","journal-title":"Hypertension"},{"issue":"12","key":"2509_CR5","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/eurheartj\/ehs262","volume":"34","author":"S Mangiafico","year":"2013","unstructured":"Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr (2013) Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J 34(12):886\u2013893c. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehs262","journal-title":"Eur Heart J"},{"issue":"3","key":"2509_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00004872-199203000-00011","volume":"10","author":"JE O'Connell","year":"1992","unstructured":"O'Connell JE, Jardine AG, Davidson G, Connell JM (1992) Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens 10(3):271\u2013277","journal-title":"J Hypertens"},{"issue":"8","key":"2509_CR7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJM199908193410806","volume":"341","author":"RW Schrier","year":"1999","unstructured":"Schrier RW, Abraham WT (1999) Hormones and hemodynamics in heart failure. N Engl J Med 341(8):577\u2013585. \n                    https:\/\/doi.org\/10.1056\/NEJM199908193410806","journal-title":"N Engl J Med"},{"issue":"7","key":"2509_CR8","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1517\/13543784.2013.797962","volume":"22","author":"J Segura","year":"2013","unstructured":"Segura J, Salazar J, Ruilope LM (2013) Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition. Expert Opin Investig Drugs 22(7):915\u2013925. \n                    https:\/\/doi.org\/10.1517\/13543784.2013.797962","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"2509_CR9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1124\/pr.110.002907","volume":"62","author":"SH Francis","year":"2010","unstructured":"Francis SH, Busch JL, Corbin JD, Sibley D (2010) cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 62(3):525\u2013563. \n                    https:\/\/doi.org\/10.1124\/pr.110.002907","journal-title":"Pharmacol Rev"},{"issue":"10","key":"2509_CR10","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1161\/hc1002.105186","volume":"105","author":"E Schulz","year":"2002","unstructured":"Schulz E, Tsilimingas N, Rinze R, Reiter B, Wendt M, Oelze M, Woelken-Weckmuller S, Walter U, Reichenspurner H, Meinertz T, Munzel T (2002) Functional and biochemical analysis of endothelial (dys)function and NO\/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation 105(10):1170\u20131175","journal-title":"Circulation"},{"issue":"25","key":"2509_CR11","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/CIR.0000000000000134","volume":"130","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ (2014) 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines. Circulation 130(25):e344\u2013e426. \n                    https:\/\/doi.org\/10.1161\/CIR.0000000000000134","journal-title":"Circulation"},{"issue":"21","key":"2509_CR12","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1161\/CIRCULATIONAHA.107.183885","volume":"115","author":"C Rosendorff","year":"2007","unstructured":"Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr, Kaplan NM, O'Connor CM, O'Gara PT, Oparil S, American Heart Association Council for High Blood Pressure R, American Heart Association Council on Clinical C, American Heart Association Council on E, Prevention (2007) Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 115(21):2761\u20132788. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.183885","journal-title":"Circulation"},{"issue":"3","key":"2509_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/sj.jhh.1001683","volume":"18","author":"B Williams","year":"2004","unstructured":"Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Mc GTS, British Hypertension S (2004) Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 18(3):139\u2013185. \n                    https:\/\/doi.org\/10.1038\/sj.jhh.1001683","journal-title":"J Hum Hypertens"},{"issue":"5A","key":"2509_CR14","doi-asserted-by":"publisher","first-page":"21C","DOI":"10.1016\/S0002-9149(99)00044-2","volume":"83","author":"DJ Webb","year":"1999","unstructured":"Webb DJ, Freestone S, Allen MJ, Muirhead GJ (1999) Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 83(5A):21C\u201328C","journal-title":"Am J Cardiol"},{"issue":"1","key":"2509_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1365-2125.2004.02243.x","volume":"59","author":"AF Kernohan","year":"2005","unstructured":"Kernohan AF, McIntyre M, Hughes DM, Tam SW, Worcel M, Reid JL (2005) An oral yohimbine\/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. Br J Clin Pharmacol 59(1):85\u201393. \n                    https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02243.x","journal-title":"Br J Clin Pharmacol"},{"issue":"30","key":"2509_CR16","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1093\/eurheartj\/ehv142","volume":"36","author":"C Bavishi","year":"2015","unstructured":"Bavishi C, Messerli FH, Kadosh B, Ruilope LM, Kario K (2015) Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. Eur Heart J 36(30):1967\u20131973. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehv142","journal-title":"Eur Heart J"},{"issue":"16","key":"2509_CR17","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S0002-9149(99)80750-4","volume":"75","author":"T Tsutamoto","year":"1995","unstructured":"Tsutamoto T, Kinoshita M, Hisanaga T, Maeda Y, Maeda K, Wada A, Fukai D, Yoshida S (1995) Comparison of hemodynamic effects and plasma cyclic guanosine monophosphate of nicorandil and nitroglycerin in patients with congestive heart failure. Am J Cardiol 75(16):1162\u20131165","journal-title":"Am J Cardiol"},{"issue":"1","key":"2509_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1161\/01.CIR.88.1.29","volume":"88","author":"H Watanabe","year":"1993","unstructured":"Watanabe H, Kakihana M, Ohtsuka S, Enomoto T, Yasui K, Sugishita Y (1993) Platelet cyclic GMP. A potentially useful indicator to evaluate the effects of nitroglycerin and nitrate tolerance. Circulation 88(1):29\u201336","journal-title":"Circulation"},{"issue":"1","key":"2509_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1073\/pnas.0710387105","volume":"105","author":"LW Nausch","year":"2008","unstructured":"Nausch LW, Ledoux J, Bonev AD, Nelson MT, Dostmann WR (2008) Differential patterning of cGMP in vascular smooth muscle cells revealed by single GFP-linked biosensors. Proc Natl Acad Sci U S A 105(1):365\u2013370. \n                    https:\/\/doi.org\/10.1073\/pnas.0710387105","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2509_CR20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/153537020523000403","volume":"230","author":"J Su","year":"2005","unstructured":"Su J, Scholz PM, Weiss HR (2005) Differential effects of cGMP produced by soluble and particulate guanylyl cyclase on mouse ventricular myocytes. Exp Biol Med (Maywood) 230(4):242\u2013250","journal-title":"Exp Biol Med (Maywood)"},{"issue":"4","key":"2509_CR21","doi-asserted-by":"publisher","first-page":"C891","DOI":"10.1152\/ajpcell.00590.2002","volume":"285","author":"FJ Rivero-Vilches","year":"2003","unstructured":"Rivero-Vilches FJ, de Frutos S, Saura M, Rodriguez-Puyol D, Rodriguez-Puyol M (2003) Differential relaxing responses to particulate or soluble guanylyl cyclase activation on endothelial cells: a mechanism dependent on PKG-I alpha activation by NO\/cGMP. Am J Physiol Cell Physiol 285(4):C891\u2013C898. \n                    https:\/\/doi.org\/10.1152\/ajpcell.00590.2002","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"2509_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1152\/jappl.2002.92.1.257","volume":"92","author":"EH Rho","year":"2002","unstructured":"Rho EH, Perkins WJ, Lorenz RR, Warner DO, Jones KA (2002) Differential effects of soluble and particulate guanylyl cyclase on Ca(2+) sensitivity in airway smooth muscle. J Appl Physiol (1985) 92(1):257\u2013263. \n                    https:\/\/doi.org\/10.1152\/jappl.2002.92.1.257","journal-title":"J Appl Physiol (1985)"},{"issue":"1","key":"2509_CR23","doi-asserted-by":"publisher","first-page":"H146","DOI":"10.1152\/ajpheart.2001.281.1.H146","volume":"281","author":"CY Hart","year":"2001","unstructured":"Hart CY, Hahn EL, Meyer DM, Burnett JC Jr, Redfield MM (2001) Differential effects of natriuretic peptides and NO on LV function in heart failure and normal dogs. Am J Physiol Heart Circ Physiol 281(1):H146\u2013H154. \n                    https:\/\/doi.org\/10.1152\/ajpheart.2001.281.1.H146","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"34","key":"2509_CR24","doi-asserted-by":"publisher","first-page":"25892","DOI":"10.1074\/jbc.M000786200","volume":"275","author":"O Zolle","year":"2000","unstructured":"Zolle O, Lawrie AM, Simpson AW (2000) Activation of the particulate and not the soluble guanylate cyclase leads to the inhibition of Ca2+ extrusion through localized elevation of cGMP. J Biol Chem 275(34):25892\u201325899. \n                    https:\/\/doi.org\/10.1074\/jbc.M000786200","journal-title":"J Biol Chem"},{"issue":"1","key":"2509_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1378\/chest.79.1.69","volume":"79","author":"NS Hill","year":"1981","unstructured":"Hill NS, Antman EM, Green LH, Alpert JS (1981) Intravenous nitroglycerin. A review of pharmacology, indications, therapeutic effects and complications. Chest 79(1):69\u201376","journal-title":"Chest"},{"issue":"4","key":"2509_CR26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/1755-5922.12183","volume":"34","author":"Z Kobalava","year":"2016","unstructured":"Kobalava Z, Kotovskaya Y, Averkov O, Pavlikova E, Moiseev V, Albrecht D, Chandra P, Ayalasomayajula S, Prescott MF, Pal P, Langenickel TH, Jordaan P, Rajman I (2016) Pharmacodynamic and pharmacokinetic profiles of sacubitril\/valsartan (LCZ696) in patients with heart failure and reduced ejection fraction. Cardiovasc Ther 34(4):191\u2013198. \n                    https:\/\/doi.org\/10.1111\/1755-5922.12183","journal-title":"Cardiovasc Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-018-2509-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2509-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2509-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T23:46:03Z","timestamp":1568936763000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-018-2509-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,4]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["2509"],"URL":"https:\/\/doi.org\/10.1007\/s00228-018-2509-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2018,7,4]]},"assertion":[{"value":"12 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Ethics Committee of the Land Berlin, was designed in accordance with the International Conference on Harmonization tripartite guideline and conducted in compliance with the ethical principles of the Declaration of Helsinki of the World Medical Association.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"U.S, S.A, J.B, P.P, M.P, G.S, M.H and T.L were employees of Novartis during the conduct of this study. G.G has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}